TAS2R46: A Potential Drug Target for Alzheimer's and Parkinson's

Target Name: TAS2R46

NCBI ID: G259292

TAS2R46

TAS2R46: A Potential Drug Target for Alzheimer's and Parkinson's

TAS2R46 is a protein that is expressed in human tissues and is known for its role in the regulation of the blood-brain barrier. It is made by the liver and has been shown to play a key role in the development and maintenance of this barrier, which is responsible for separating the brain from the body and ensuring the safe delivery of drugs and other substances into the brain.

Recent studies have suggested that TAS2R46 may be a drug target or biomarker for a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. This is because TAS2R46 has been shown to interact with a variety of molecules that are involved in the development and progression of these disorders.

One of the ways that TAS2R46 may be involved in the development of Alzheimer's disease is by contributing to the formation of neurofibrillary tangles, which are thought to play a key role in the destruction of nerve cells in this disease. Studies have shown that TAS2R46 is expressed in the brains of people with Alzheimer's disease and that it is involved in the development of these tangles. Additionally, TAS2R46 has been shown to interact with a protein called Tau, which is also thought to be involved in the development of Alzheimer's disease.

Another potential role for TAS2R46 in the development of Parkinson's disease is by contributing to the loss of dopamine-producing neurons in the brain. Parkinson's disease is characterized by the loss of motor and non-motor neurons in the brain, and it is thought to be caused by a deficiency of dopamine. TAS2R46 has been shown to interact with dopamine-producing neurons and has been shown to be involved in the regulation of dopamine signaling in the brain.

In addition to its potential role in the development of Alzheimer's and Parkinson's disease, TAS2R46 has also been suggested as a potential biomarker for these disorders. Studies have shown that TAS2R46 levels are elevated in the brains of people with Alzheimer's disease and Parkinson's disease, and that these levels are correlated with the severity of the disorders. Additionally, TAS2R46 has been shown to be involved in the regulation of neurotransmitter signaling in the brain, which is thought to be involved in the development and progression of these disorders.

Overall, the study of TAS2R46 has shown that it is involved in the regulation of the blood-brain barrier and may be a drug target or biomarker for the development and progression of Alzheimer's and Parkinson's disease. Further research is needed to fully understand the role of TAS2R46 in these disorders and to develop effective treatments.

Protein Name: Taste 2 Receptor Member 46

Functions: Receptor that may play a role in the perception of bitterness and is gustducin-linked. May play a role in sensing the chemical composition of the gastrointestinal content. The activity of this receptor may stimulate alpha gustducin, mediate PLC-beta-2 activation and lead to the gating of TRPM5 (By similarity). In airway epithelial cells, binding of bitter compounds increases the intracellular calcium ion concentration and stimulates ciliary beat frequency (By similarity)

The "TAS2R46 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAS2R46 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets